The title compound, [Bi(C4H8NOS2)2I(C12H8N2)], is monomeric, with the Bi(III) atom chelated by the two S atoms of two morpholine-4-carbodi-thio-ate ligands and the two N atoms of a 1,10-phenanthroline ligand. An iodide ligand completes the coordination sphere, with the seven-coordinate Bi(III) atom adopting a highly distorted monocapped octa-hedral geometry.

The molecular conformation of the title compound, C(10)H(16)N(2)O(4), is determined by an intra-molecular N-H⋯O hydrogen bond involving the morpholine NH group and the amide O atom. In the crystal, mol-ecules are linked by N-H⋯O hydrogen bonds into chains along the a-axis direction.

The title compound, C(9)H(10)N(2)O(2)S, was obtained from the treatment of ethyl 4-cyano-3-hydr-oxy-5-morpholinothio-phene-2-carboxyl-ate with concentrated HCl. The mean plane of the essentially planar dihydro-thio-phene ring is almost orthogonal to the mirror plane of the N-morpholine substituent, making a dihedral angle of 87.2 (2)°.

The title compound, C(20)H(23)N(3)O(6)S, crystallizes with two crystallographically independent mol-ecules in the asymmetric unit. The thio-morpholine ring in both mol-ecules adopts a chair conformation. The crystal structure is stabilized by C-H⋯O inter-actions. The amino groups are shielded and, as a result, these groups are not involved in hydrogen bonding.

In the title compound, C(11)H(14)N(2)O(2), the urea-type NC=ON moiety [planar to within 0.0002 (13) Å] is inclined to the phenyl ring by 42.88 (8) Å, and the morpholine ring has a chair conformation. In the crystal, inter-molecular N-H⋯O hydrogen bonds link the mol-ecules into infinite chains in [001].

The title ion pair, C(18)H(19)N(2)O(+)·NO(3) (-), features an N-H⋯O hydrogen bond linking the cation to the anion. The morpholine portion adopts a chair conformation; the aromatic rings of the biphenyl-ene portion are twisted [torsion angles for the four atoms involving the ar-yl-aryl bond = 35.1 (2)-40.4 (2)°].

In the title molecular salt, C(9)H(18)NO(+)·Cl(-), the morpholine ring adopts a chair conformation. In the crystal structure, intra-molecular C-H⋯Cl bonds occur and inter-molecular C-H⋯O and C-H⋯Cl hydrogen bonds link the mol-ecules.

Ribosomes containing 5S RNA in which the 3'-terminus has been modified chemically, either by periodate oxidation or by conversion of the terminal ribose to a morpholine derivative, are fully as active in peptidebond formation and polypeptide synthesis as those ribosomes with unmodified 5S RNA. These results exclude models for protein synthesis in which peptidyl-5S RNA is formed as an intermediate.

The title compound, C(6)H(13)ClNO(+)·C(6)H(2)N(3)O(7) (-), was synthesized from picric acid and 4-(2-chloro-ethyl)morpholine. The crystal structure is stabilized by C-H⋯O and N-H⋯O hydrogen-bond inter-actions.

The asymmetric unit of the title compound, C(13)H(20)NO(+)·PF(6) (-), contains two cations, one complete anion and two half hexa-fluoro-phosphate anions having crystallographically imposed twofold rotation symmetry. In the cations, the morpholine rings are in a chair conformation. In the crystal, ions are linked by weak C-H⋯F hydrogen bonds into a three-dimensional network.